For research use only. Not for therapeutic Use.
Vapendavir（Cat No.:R031259）is a potent antiviral compound developed as a selective inhibitor of enterovirus replication. It specifically targets the viral RNA-dependent RNA polymerase, disrupting the replication process of enteroviruses, including rhinoviruses, which are responsible for the common cold. By inhibiting viral replication, Vapendavir demonstrates potential therapeutic efficacy against respiratory infections, particularly those caused by rhinoviruses. Its clinical development aims to address unmet needs in managing viral respiratory diseases, providing an innovative approach to antiviral therapy. Vapendavir is undergoing clinical trials to assess its safety and efficacy in human patients.
| Catalog Number | R031259 |
| CAS Number | 439085-51-5 |
| Synonyms | BTA 798; 3-Ethoxy-6-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-1,2-benzisoxazole |
| Molecular Formula | C21H26N4O3 |
| Purity | ≥95% |
| Target | Enterovirus |
| Storage | -20°C |
| IUPAC Name | 3-ethoxy-6-[2-[1-(6-methylpyridazin-3-yl)piperidin-4-yl]ethoxy]-1,2-benzoxazole |
| InChI | InChI=1S/C21H26N4O3/c1-3-26-21-18-6-5-17(14-19(18)28-24-21)27-13-10-16-8-11-25(12-9-16)20-7-4-15(2)22-23-20/h4-7,14,16H,3,8-13H2,1-2H3 |
| InChIKey | DKSVBVKHUICELN-UHFFFAOYSA-N |
| SMILES | CCOC1=NOC2=C1C=CC(=C2)OCCC3CCN(CC3)C4=NN=C(C=C4)C |
| Reference | 1:Antimicrob Agents Chemother. 2014 Nov;58(11):6990-2. doi: 10.1128/AAC.03328-14. Epub 2014 Sep 8. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication.Tijsma A,Franco D,Tucker S,Hilgenfeld R,Froeyen M,Leyssen P,Neyts J, PMID: 25199773 PMCID: PMC4249361 DOI: 10.1128/AAC.03328-14 </br><span>Abstract:</span> Antivirals against enterovirus 71 (EV71) are urgently needed. We demonstrate that the novel enteroviral protease inhibitor (PI) SG85 and capsid binder (CB) vapendavir efficiently inhibit the in vitro replication of 21 EV71 strains/isolates that are representative of the different genogroups A, B, and C. The PI rupintrivir, the CB pirodavir, and the host-targeting compound enviroxime, which were included as reference compounds, also inhibited the replication of all isolates. Remarkably, the CB compound pleconaril was devoid of any anti-EV71 activity. An in silico docking study revealed that pleconaril-unlike vapendavir and pirodavir-lacks essential binding interactions with the viral capsid. Vapendavir and SG85 (or analogues) should be further explored for the treatment of EV71 infections. The data presented here may serve as a reference when developing yet-novel inhibitors. Copyright © 2014, American Society for Microbiology. All Rights Reserved. |
